Alder BioPharmaceuticals prices upsized IPO at $10, well below the range

By Renaissance Capital,

Shutterstock photo

Alder BioPharmaceuticals, which is developing antibodies to prevent migraine and treat rheumatoid arthritis, raised $80 million by offering 8.0 million shares at $10, below its proposed $13 to $15 range. Alder BioPharmaceuticals will list on the NASDAQ under the symbol ALDR. Credit Suisse and Leerink Partners acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ALDR

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by